XVA143 biochemical

XVA143

Cat. Num. AAA228556

• Purity: 98%
• Synonyms: XVA143; N/A; 26RFa (mouse, rat); XVA143 biochemical

• Purity/Purification: 98%

• CAS: 264275-77-6
• Solubility: <1mg/ml refers to the product slightly soluble or insoluble
• In vitro: XVA143 (1 uM) completely abolishes binding of ICAM-1 to LFA-1 in Mn 2+ and Mg 2+ /EGTA, with no hint of agonism[1]. XVA143 restores rolling of the alpha L -E310A beta 2 mutant by inducing extension of alpha L[2]. Cell Viability Assay[1]Cell Line: K562 cells. Concentration: 0, 0.2, 0.5 and 1 uM. Incubation Time:. Result: Potent against the weakest activator (2 mM Mg 2+ /1 mM EGTA, IC 50 ~10 -3 nM) and least potent against the strongest activator (1 mM Mn 2+, IC 50 ~10 -3 nM). Cell Viability Assay[1]Cell Line: Wild-type murine lymphocytes[1]. Concentration: 100 uM. Incubation Time:. Result: Induced a 50% increase in rolling fraction compared to vehicle-treated control cells ((from 27+/-5% to 41+/-7%).
• Preparation and Storage: Powder: -20 degree C for 3 years; In solvent: -80 degree C for 2 years

Structure

(Orphan GPCR SP9155 agonist P550 (mouse, rat), CAS 600171-70-8)

Structure

(Orphan GPCR SP9155 agonist P550 (mouse, rat), CAS 600171-70-8)

Related Product Information for XVA143 biochemical

XVA143, an alpha/beta I-like allosteric antagonist, inhibits LFA-1 dependent firm adhesion, while at the same time it enhances adhesion in shear flow and rolling both in vitro and in vivo.

References

1. Chartrel N, et al. Identification of 26RFa, a hypothalamic neuropeptide of the RFamide peptide family with orexigenic activity. Proc Natl Acad Sci U S A. 2003;100(25):15247-15252.
2. Chartrel N, et al. The Neuropeptide 26RFa (QRFP) and Its Role in the Regulation of Energy Homeostasis: A Mini-Review. Front Neurosci. 2016;10:549. Published 2016 Nov 29.
3. Egido EM, et al. 26RFa, a novel orexigenic neuropeptide, inhibits insulin secretion in the rat pancreas. Peptides. 2007;28(4):725-730.